Praxis Precision Medicines
- Market cap
- 7.76B
- P/E (TTM)i
- -21.45
- P/Bi
- 5.79
- EPSi
- -13.48
- Div yieldi
- 0.00%
- 52W posi
- 66%
Anonymous reader poll. Unscientific, not investment advice.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
- Founded
- 2015
- CEO
- Mr. Marcio Souza
- Employees
- 168
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- praxismedicines.com
Company profile
- Exchange
- US
- Symbol
- PRAX
- Market-cap rank
- #1645
- Listing date
- 2020-10-16
- Market cap
- 7.76B
- Float cap
- 6.69B
- Shares out
- 27.92M
- Float shares
- 24.08M
Sectors & themes
Quote time 2026-10-08 04:00:01 · For reference only, not investment advice and not tailored to your situation.